Myositis News and Research

RSS

Myositis is inflammation of your skeletal muscles, which are also called the voluntary muscles. These are the muscles you consciously control that help you move your body. An injury, infection or autoimmune disease can cause myositis. The diseases dermatomyositis and polymyositis both involve myositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Both diseases are usually treated with prednisone, a steroid medicine, and sometimes other medicines.

COVID-19 linked to rise in autoimmune lung disease, study finds

A study in eBioMedicine identifies shared immunopathology between SARS-CoV-2 infection and MDA5 autoimmunity, highlighting a surge in MDA5+ cases and interstitial lung disease during the COVID-19 pandemic.

15 May 2024

Investigating the efficacy and safety of existing drugs in patients with rare immune diseases

This month the first study within the DRIMID consortium (DRIMID stands for Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases) has started.

23 Apr 2024

Researchers identify the culprit responsible for harmful inflammation in certain muscular disorders

Inflammation is an important part of the body's defenses, eliminating threats and repairing damage. When the immune system is overactivated, though, it can turn from friend to foe.

14 Dec 2023

In-depth assessment of muscle biopsies in patients with long COVID

Researchers analyzed skeletal muscle biopsies of patients with persistent fatigue and malaise post-exertion to determine the underlying mechanisms of long COVID.

20 Feb 2023

Proteomics reveals a distinct IFN-driven plasma cytokine response to COVID-19 in infants and young children

Researchers assesses immune responses to SARS-CoV-2 shortly after birth using a multi-omics approach.

5 Feb 2023

Researchers devise new biomarker-based strategy to screen for myocarditis caused by cancer treatment

Researchers at Michigan Medicine have devised a new biomarker-based strategy to screen for a rare and deadly complication caused by monoclonal antibodies used to treat several cancers.

20 Dec 2022

SARS-CoV-2 activates NLRP3 inflammasome

Researchers assessed the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the NLR family pyrin domain containing 3 (NLRP3) inflammasome activation.

7 Nov 2022

The health status and exercise capacity of COVID-19 survivors one year after hospital discharge

A recent study evaluated the health status and exercise capacity of COVID-19-recovered patients one year after hospital discharge.

13 Oct 2022

Post-acute sequelae of SARS-CoV-2 infection in children appears to be lower than in adults

A new study conducted by the National Institutes of Health (NIH) RECOVER Pediatric Electronic Health Records (EHR) Cohort and authored by Suchitra Rao, MD, infectious disease specialist at Children's Hospital Colorado, found that the risk of post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID, in children appears to be lower than what has been reported in adults.

29 Aug 2022

Targeting necroptosis using a necroptosis inhibitor lessens myositis-induced muscle weakness

A new study has suggested that treatment to target necroptosis in muscle fibers using a necroptosis inhibitor lessens myositis-induced muscle weakness as well as muscle cell death and inflammation in the muscles. This has been shown to be a promising strategy for treating polymyositis.

2 Mar 2022

EULAR develops new recommendations for cardiovascular risk management

EULAR, the European Alliance of Associations for Rheumatology, has developed new recommendations for CVR management in people with gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), and antiphospholipid syndrome (APS).

23 Feb 2022

Current understanding of the link between COVID-19 and cardiovascular disease

A review published in Chemo-Biological Interactions has focused on the prevalence of COVID-19 in CVD patients associated with ACE2 mechanisms.

10 Nov 2021

Breakthrough SARS-CoV-2 infections in patients with systemic rheumatic diseases

A recent study discusses the clinical characteristics and outcomes of patients with SARDs who were previously vaccinated against SARS-CoV-2.

11 Aug 2021

Researchers identify mechanism by which dermatomyositis may develop in humans

Dermatomyositis is an idiopathic inflammatory myopathy that has been regarded as an autoimmunity-based disorder, although its pathogenesis remains unclear.

8 Apr 2021

UCI receives $4.2 million grant to study sporadic inclusion body myositis affecting aging adults

The National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded UCI a 5-year, $4.2 million grant to study sporadic inclusion body myositis (sIBM), which affects aging adults causing asymmetric muscle weakness and severe disability. The disease is currently untreatable and poorly understood.

6 Apr 2021

Anti-phospholipid antibodies in severely ill patients not distinctive to COVID-19, says study

A new study by researchers at the University of Toronto and the University of Calgary in Canada indicates that the presence of these antibodies correlates with more severe COVID-19 symptoms and signs.

25 Feb 2021

Radiological images reveal how COVID virus can trigger the body to attack itself

Muscle soreness and achy joints are common symptoms among COVID-19 patients. But for some people, symptoms are more severe, long-lasting, and even bizarre, including rheumatoid arthritis flares, autoimmune myositis, or "COVID toes."

18 Feb 2021

SARS-CoV-2 triggers development of new-onset IgG autoantibodies in hospitalized COVID-19 patients

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent for coronavirus disease 2019 (COVID-19), is associated with several clinical features common in autoimmune diseases as myalgias, arthralgias, fatigue, and rashes. COVID-19 patients also exhibit less common autoimmunity manifestations such as myositis, thrombosis, myocarditis, encephalitis, vasculitis, and arthritis.

1 Feb 2021

EULAR publishes recommendations for management of rheumatic immune-related adverse events

The European League Against Rheumatism, EULAR, has published recommendations around rheumatic immune-related adverse events caused by cancer treatment with checkpoint inhibitors.

8 May 2020

Autoimmunity appears to be increasing in the U.S.

Autoimmunity, a condition in which the body's immune system reacts with components of its own cells, appears to be increasing in the United States, according to scientists at the National Institutes of Health and their collaborators.

8 Apr 2020